仙琚制药：公司正经历从传统仿制药向创新药转型的过程

Core Viewpoint - The company is undergoing a transformation from traditional generic drugs to innovative drugs, with plans for multiple complex formulations and new drug applications in the future [1] Group 1: Company Strategy - The company has gradually shifted its sales team, production, and R&D registration capabilities over the past two to three years [1] - The company aims to explore and discover new targets based on clinical needs and disease mechanisms [1] Group 2: R&D Focus - The company is committed to an innovation-driven development path, including steroid-based innovations and seeking more attractive innovative products beyond steroid limitations in certain therapeutic areas [1] Group 3: Manufacturing and Sales - The company is determined to become an excellent comprehensive manufacturing platform for global steroid hormones [1] - The company will continue to strengthen the capabilities of its self-operated sales team to prepare for the commercial transformation of future innovative products [1]